STOCK TITAN
  1. Home
  2. Sec-filings
  3. EXOZ
  4. [8-K] EXOZYMES INC. Reports Material Event

eXoZymes (NASDAQ: EXOZ) files updated NCTx investor presentation

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

eXoZymes Inc. filed a current report to make public an updated Investor Presentation for its NCTx business as of March 30, 2026. The company characterizes this under an Other Events item, using the 8-K to furnish the new presentation as Exhibit 99.1.

Positive

  • None.

Negative

  • None.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Investor Presentation financial
"Attached is an updated Investor Presentation of eXoZymes Inc., a Nevada corporation, as of March 30, 2026"
An investor presentation is a carefully prepared talk or visual display that explains a company's business, goals, and financial performance. It helps investors understand how the company operates and its future prospects, much like a report card or progress update. These presentations are important because they provide transparency and help investors decide whether to support or invest in the company.
Other Events regulatory
"Item 8.01 — Other Events. Attached is an updated Investor Presentation"
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Understanding 8-K Material Events →
false 0002010788 0002010788 2026-03-30 2026-03-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

Current Report Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):

March 30, 2026

 

EXOZYMES INC.

(Exact name of registrant as specified in its charter)

 

Nevada   001-42204   83-4550057

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

750 Royal Oaks Drive, Suite 106

Monrovia, CA 91016

(Address of principal executive offices and zip code)

 

Registrant’s telephone number, including area code: (626) 415-1488

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Exchange Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   EXOZ   Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 8.01 — Other Events.

 

Attached is an updated Investor Presentation of eXoZymes Inc., a Nevada corporation, as of March 30, 2026, in connection with its NCTx business.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibits   Description of Exhibit
     
99.1   Investor Presentation of eXoZymes Inc. for NCTx as of March 30, 2026.
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL Document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: March 30, 2026 EXOZYMES INC.
     
  By /s/ Fouad Nawaz
    Fouad Nawaz,
    Vice President, Finance

 

 

 

 

Exhibit 99.1

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 

 

Source: View Original Filing on SEC EDGAR

FAQ

What did eXoZymes (EXOZ) disclose in this 8-K filing?

eXoZymes Inc. used this 8-K to furnish an updated Investor Presentation for its NCTx business, dated March 30, 2026. The presentation is attached as Exhibit 99.1 and is treated as an informational "Other Events" disclosure.

What is the main focus of eXoZymes’ updated investor presentation?

The filing states that the attached Investor Presentation relates to eXoZymes Inc.’s NCTx business. It is described as an updated presentation as of March 30, 2026, but the specific business details and metrics appear only within the attached exhibit.

Which exhibit did eXoZymes attach to this EXOZ 8-K?

eXoZymes Inc. attached Exhibit 99.1, described as an Investor Presentation for NCTx as of March 30, 2026. The filing also includes Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.

Does this eXoZymes 8-K include financial statements or earnings data?

This 8-K is filed under the Other Events item and highlights an updated investor presentation. It lists no separate financial statements or earnings metrics in the body of the report, directing readers instead to the attached Exhibit 99.1 for information.

On which exchange is eXoZymes (EXOZ) common stock listed?

The filing notes that eXoZymes Inc.’s common stock, trading under the symbol EXOZ, is listed on the Nasdaq Capital Market. This information appears in the section describing securities registered under Section 12(b) of the Exchange Act.

Filing Exhibits & Attachments

82 documents

Press Releases

Other Documents

eXoZymes Inc

NASDAQ:EXOZ

View EXOZ Stock Overview →

EXOZ Rankings

#5478 Ranked by Market Cap
N/A Ranked by Dividends

EXOZ Latest News

Mar 25, 2026
eXoZymes to Host Fourth Quarter and Full Year 2025 Results Conference Call on Tuesday March 31, 2026
Mar 18, 2026
Successful Pilot Scale Run with Cayman Chemical Validates eXoZymes' Technology and Scalability
Mar 12, 2026
eXoZymes' CCO Damien Perriman to Present a NCT Solution at Next Week's MISTA Symposium
Feb 10, 2026
With Refreshed Brand eXoZymes Sharpens Pharmaceutical Focus to Drive Platform Leverage and Long-Term Value Creation
Jan 29, 2026
eXoZymes Advancing Commercial Readiness With Profound Production Metrics on Initial NCT Pilot Run

EXOZ Latest SEC Filings

Mar 30, 2026
[10-K] EXOZYMES INC. Files Annual Report
Feb 4, 2026
[8-K] EXOZYMES INC. Reports Material Event
Jan 26, 2026
[424B2] EXOZYMES INC. Prospectus Supplement
Jan 26, 2026
[EFFECT] EXOZYMES INC. SEC Filing
Jan 16, 2026
[S-3] EXOZYMES INC. Shelf Registration Statement

EXOZ Stock Data

60.06M
2.38M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United States
MONROVIA